Anjeza Gjino promoted to Chief Monetary Officer; Invoice Huyett to transition to Strategic Advisor
Cheryl Gault promoted to Chief Working Officer
Amy Schulman stepping down from Board of Administrators
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical firm creating progressive medicines for folks with critical illnesses of the central nervous system (CNS), right now introduced, efficient January 1, 2021, the promotions of Cheryl Gault to Chief Working Officer and Anjeza Gjino to Chief Monetary Officer. Invoice Huyett, the Firm’s present CFO, will proceed to work part-time as a Strategic Advisor offering strategic, operational, and organizational growth perception.
Cyclerion additionally introduced that Amy Schulman, Managing Director of Polaris Companions, can be stepping down from the Board of Administrators. Terrance McGuire, Co-founder and Common Associate of Polaris Companions, continues to serve on the Board of Administrators.
“Cyclerion places a excessive precedence on recruiting and creating excellent expertise and making ready them to tackle broader obligations. Cheryl and Anjeza are terrific leaders who’ve made essential contributions to Cyclerion, and I congratulate them on their expanded roles. I’m happy that we are going to proceed to profit from Invoice’s strategic acumen going ahead. I additionally need to specific my deep appreciation to Amy Schulman for her service as a founding member of the Firm’s Board of Administrators,” mentioned Peter Hecht, Ph.D., Cyclerion’s Chief Government Officer.
The Cyclerion government group immediately reporting to Dr. Hecht contains Andy Busch, Ph.D., Chief Scientific Officer; Cheryl Gault, Chief Working Officer; Anjeza Gjino, Chief Monetary Officer; and Chris Wright, M.D., Ph.D., Chief Medical Officer.
Anjeza Gjino was Vice President, Finance and Company Secretary and helped lead the execution of the Firm’s spin-off, the creation of the Firm’s monetary programs and processes, its strategic funding and capital allocation efforts, and likewise has served as Company Secretary. Beforehand, Ms. Gjino served as head of Monetary Planning and Evaluation at Ironwood Prescription drugs, supporting the transition to commercialization. Earlier, Ms. Gjino held numerous finance roles at PerkinElmer. Whereas at Ironwood and PerkinElmer, she supplied monetary counsel that included strategic planning, portfolio optimization, enterprise growth and business execution. Ms. Gjino holds an MBA from the Massachusetts Institute of Expertise and a BS in company finance from Bentley College.
Cheryl Gault was Senior Vice President and Head of Technique and Company Growth. Ms. Gault has been liable for company and enterprise growth, program administration, portfolio technique, new product planning, and company technique features. Beforehand, Ms. Gault served as Vice President, Industrial Technique & New Product Planning at Ironwood, the place she partnered with the R&D group to advance differentiated pipeline packages and performed a central position within the launch of LINZESS®, the market chief in irritable bowel illness. Previous to that, she was at Genzyme Company in a wide range of gross sales and advertising roles within the biosurgery division, together with in a management position within the launch of Synvisc-ONE, an injectable for the therapy of osteoarthritis. Ms. Gault obtained her BA in advertising from Boston Faculty.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical firm targeted on discovering, creating and commercializing progressive medicines for folks with critical illnesses of the central nervous system (CNS). Cyclerion’s lead program is CY6463, beforehand often known as IW-6463, a pioneering CNS-penetrant sGC stimulator in medical growth for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer’s Illness with Vascular pathology (ADv).
For extra details about Cyclerion, please go to https://www.cyclerion.com/ and observe us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/firm/cyclerion).
Ahead Wanting Assertion –
This press launch comprises forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. Our forward-looking statements are primarily based on present beliefs and expectations of our administration group that contain dangers, potential adjustments in circumstances, assumptions, and uncertainties. We could, in some circumstances use phrases corresponding to “predicts,” “believes,” “potential,” “proceed,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “could,” “might,” “would possibly,” “probably,” “will,” “ought to” or different phrases that convey uncertainty of the long run occasions or outcomes to determine these forward-looking statements. Every forward-looking assertion is topic to dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied in such assertion. Relevant dangers and uncertainties embrace the dangers listed below the heading “Threat Components” and elsewhere in our 2019 Type 10-Ok filed on March 12, 2020, and in Cyclerion’s subsequent SEC filings, together with the Type 10-Qs filed on Could 4, 2020, August 3, 2020 and November 5, 2020. Traders are cautioned to not place undue reliance on these forward-looking statements. These forward-looking statements (besides as in any other case famous) communicate solely as of the date of this press launch, and Cyclerion undertakes no obligation to replace these forward-looking statements, besides as required by regulation.
Carlo Tanzi, Ph.D.
Kendall Investor Relations